Expert Interview
Discussing Terns Pharmaceuticals' TERN-701 in relapsed/refractory CML and its phase 1 data presented at ASH2025
Ticker(s): TERNInstitution: Vanderbilt University Medical Center
- Assistant Professor of Medicine, Hematology/Oncology at Vanderbilt University Medical Center
- Manages 60 patients with Myelofibrosis and 10+ with CML
- Completed fellowship in experimental therapeutics from Taussig Cancer institute in 2021 and research focuses on cancer biology
How are you currently managing CML in both frontline and r/r?
Added By: wilson_adminHow is Scemblix currently being used?
Added By: wilson_adminWhat would it take for TERN-701 to supplant Scemblix?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
